Fremanezumab Shows Potential as Effective Treatment for Migraine and Comorbid Major Depressive Disorders

The UNITE trial reveals fremanezumab’s effectiveness in treating migraine and comorbid depression, offering hope for patients with overlapping conditions.:

Source: Neurology Read More

Previous PostPatient Conversation and Adoption of CSAI in Clinical Practice
Next PostEmerging Biomarkers for Monitoring Remyelination in Multiple Sclerosis: Ahmed Abdelhak, MD

Fremanezumab Shows Potential as Effective Treatment for Migraine and Comorbid Major Depressive Disorders

Previous PostPatient Conversation and Adoption of CSAI in Clinical Practice

Next PostEmerging Biomarkers for Monitoring Remyelination in Multiple Sclerosis: Ahmed Abdelhak, MD

Related Posts

<![CDATA[Phase 3 Post Hoc Analysis Shows Foslevodopa/Foscarbidopa Reduces Troublesome Dyskinesia in Advanced Parkinson Disease ]]>

<![CDATA[DMD Management: Evolving Regimens and Real-World Adherence]]>

<![CDATA[NeuroVoices: Kate Rosenbluth, PhD, on Expanding Noninvasive Treatment for Essential Tremor With Cala kIQ Plus]]>

Categories